IceCure Medical Ltd is an interventional oncology company specializing in the development, manufacturing and marketing of minimally invasive cryoablation systems for tumor treatment. Its proprietary ProSense platform delivers localized freezing temperatures to destroy targeted tissue through iceball formation. IceCure’s technology is used in percutaneous procedures to treat benign and malignant tumors in the breast, lung and soft tissue, offering clinicians an outpatient alternative to surgery with reduced risk, scarring and recovery time.
The company’s product portfolio centers on the IceSense3 cryoablation console, which powers patented single-use IceR3 cryoprobes designed for precise thermal control and efficient iceball creation. The system features real-time imaging compatibility with ultrasound and computed tomography, enabling physicians to visualize and monitor ablation margins during the procedure. IceCure holds CE Mark certification for its devices in Europe and has secured marketing authorizations in multiple international markets, including Israel, China and select countries in South America.
Founded in 2006 and headquartered in Caesarea, Israel, IceCure Medical has expanded its global footprint through strategic distribution partnerships and clinical collaborations. The company has conducted numerous clinical studies demonstrating the safety and efficacy of cryoablation in the treatment of fibroadenomas and early-stage breast cancer. IceCure continues to pursue regulatory approvals worldwide, including an active FDA Investigational Device Exemption (IDE) study in the United States to support a future premarket approval (PMA) application.
Under the leadership of Chief Executive Officer Eyal Shamir, IceCure has strengthened its management team with experienced professionals in medical device commercialization and oncology. Its board of directors comprises industry veterans who guide strategic growth and innovation initiatives. With a focus on expanding clinical indications and enhancing its product offering, IceCure Medical aims to establish cryoablation as a standard-of-care option in image-guided tumor therapies across global markets.
AI Generated. May Contain Errors.
Free ICCM Stock Alerts